Cite

HARVARD Citation

    Gratch, D. et al. (2022). Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing—Commentary. Multiple sclerosis. pp. 695-696. [Online]. 
  
Back to record